Export: +91 9820402906   Domestic: +91 7710003340 | HR: +91 9137757219
Donepezil Tablets

Donepezil Tablet Manufacturer Supplier Exporter

Healthy Life Pharma

Donepezil Tablets IP 5 mg
Each Film-Coated Tablet Contains:
Donepezil Hydrochloride IP equivalent to Donepezil 5 mg
Excipients q.s.

Usage: Symptomatic treatment of dementia associated with Alzheimer's disease under medical supervision

Category: Pharmaceutical Tablets

Therapeutic Category: Acetylcholinesterase Inhibitor / Anti-Dementia Medicine

SKU: Donepezil Tablets

Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations

Product Information

Donepezil Tablet Manufacturer Supplier Exporter is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.

For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.

Description

Donepezil Tablets (5mg / 10mg)

Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)

1. Product Introduction

Healthy Life Pharma Pvt. Ltd. is a Manufacturer of Donepezil Hydrochloride Tablets in India. Donepezil is a centrally acting acetylcholinesterase inhibitor used for symptomatic treatment of dementia associated with Alzheimer's disease. It may provide benefit in cognition and day-to-day function for some patients, but it does not cure Alzheimer's disease or stop the underlying neurodegenerative process.

We offer contract manufacturing services for Donepezil formulations according to approved product specifications. Standard film-coated tablets and orally disintegrating/mouth-dissolving dosage forms may be manufactured where separately developed, validated and registered. Patient-friendly dosage forms can be useful when swallowing conventional tablets is difficult.

2. Product Specifications

ParameterSpecification
Product NameDonepezil Tablets
Generic NameDonepezil Hydrochloride Tablets USP / BP / IP, as applicable
CAS Number120011-70-3 (Donepezil Hydrochloride)
Strength5mg / 10mg, according to registered formulation
Dosage FormFilm-Coated Tablet / ODT or MDT only where separately registered
StandardUSP / BP / IP or applicable registered specification
Therapeutic ClassAcetylcholinesterase Inhibitor / Anti-Dementia Medicine
Shelf LifeUp to 36 months where supported by product-specific stability data
Packaging10×10 / 10×15 blister, bottle or market-specific registered pack

3. Manufacturing Technology

  • ODT / MDT Technology: Where an orally disintegrating formulation is registered, suitable excipients and super-disintegrants may be used to achieve the validated disintegration profile. A universal “within 30 seconds” claim should only be made when supported by the specific product specification.
  • Film Coating: Standard tablets may use a film coating according to the registered formula to support handling, appearance, taste masking and stability.
  • Content Uniformity: Validated dispensing, blending and in-process controls help maintain consistent low-dose active distribution throughout the batch.
  • Packaging: Blister, calendar blister or bottle presentations may be supplied according to stability data and destination-market requirements.

4. Quality Assurance

  • Identity, Assay & Uniformity: Active identity, potency and dosage-unit uniformity are tested against applicable pharmacopoeial or registered criteria.
  • Dissolution: Drug release is tested using the product-specific registered method and acceptance criteria rather than a universal percentage/time target.
  • Related Substances: Relevant impurities and degradation products are monitored using validated analytical methods.
  • Stability: Shelf life and storage conditions are supported by product-specific stability studies.

5. Pharmacology and Clinical Use

Donepezil reversibly inhibits acetylcholinesterase, increasing acetylcholine availability in the central nervous system. This can provide symptomatic cognitive and functional benefit in some patients with Alzheimer's dementia.

  • Alzheimer's Disease: Used for symptomatic treatment of dementia of the Alzheimer's type according to approved labeling.
  • Expected Benefit: Response varies. Donepezil may improve or stabilize symptoms for a period in some patients, but it should not be described as reliably slowing the underlying disease process.
  • Other Dementias: Use in vascular dementia, dementia with Lewy bodies or other syndromes depends on diagnosis, evidence, local approval and specialist judgment; these should not be presented as universal approved indications.

6. Export and Regulatory Support

  • Dossier Support: CTD / ACTD documentation where applicable.
  • Bioequivalence Documentation: Provided only where product-specific studies or acceptable regulatory evidence are available and required.
  • Certificates: FSC, COPP and COA where applicable.
  • Logistics: Export support by air or sea according to applicable regulatory and commercial requirements.

7. Frequently Asked Questions

Q: Who manufactures Donepezil Tablets?
A: Healthy Life Pharma Pvt. Ltd. manufactures Donepezil tablet formulations in India.

Q: Is Donepezil available under brand names?
A: Yes. Donepezil is marketed under various brands. A product should only be described as bioequivalent or interchangeable with a particular reference product when supported by the required regulatory evidence.

Q: When should Donepezil be taken?
A: Follow the exact registered product label and prescriber's instructions. Evening dosing is common for some products, but insomnia or vivid dreams may lead clinicians to consider a different administration time for some patients.

Q: Does Donepezil cure Alzheimer's disease?
A: No. Donepezil is a symptomatic treatment. It does not cure Alzheimer's disease or reliably stop its underlying progression.


Clinical Pharmacology & Safety Information

(For Registered Medical Practitioners & Patient Reference)

8. Dosage and Administration

  • Individualized Dosing: Starting dose, titration interval and maintenance dose should follow the exact registered prescribing information and clinician assessment rather than a universal fixed schedule.
  • Higher Strengths: Specialized higher-dose formulations available in some markets are not interchangeable with standard 5mg or 10mg tablets and should not be inferred to be available from this product page.
  • Film-Coated Tablets: Take according to the specific product instructions.
  • ODT / MDT: Administration on the tongue applies only to a separately registered orally disintegrating formulation.
  • Food: Follow the specific registered label regarding food and timing.

9. Side Effects and Precautions

  • Gastrointestinal: Nausea, diarrhea, vomiting and reduced appetite can occur, particularly during initiation or dose escalation.
  • Cardiovascular: Bradycardia, syncope and heart block can occur, especially in patients with conduction disease or those using other heart-rate-lowering medicines.
  • CNS / Sleep: Dizziness, insomnia, vivid dreams, fatigue and muscle cramps may occur.
  • Weight: Reduced appetite and weight loss can occur; clinical monitoring may be appropriate.
  • Gastrointestinal Bleeding: Increased cholinergic activity may increase gastric acid secretion; caution is appropriate in patients with ulcer history or concurrent NSAID use.
  • Other Cautions: Seizure disorders, asthma/COPD, urinary obstruction and perioperative use require appropriate clinical consideration.

10. Storage Instructions

  • Store below 25°C unless otherwise specified on the registered label.
  • Keep in a dry place and protect from excessive heat, light and moisture.
  • Keep the container/package securely closed and out of reach of children.